Iambic Ther­a­peu­tics has filed to go pub­lic, the lat­est ex­am­ple in the mat­u­ra­tion of the next crop of AI-fo­cused biotech star­tups.

The San Diego-based com­pa­ny...

Celldex said its ex­per­i­men­tal treat­ment bar­zolvolimab hit its pri­ma­ry end­point in two Phase 3 tri­als, even as the read­out raised safe­ty con­cerns on two life-threat­en­ing...

Viking Ther­a­peu­tics says pa­tients who switched to a once-a-month dos­ing reg­i­men of its obe­si­ty drug did not re­gain much weight af­ter 12 weeks, bol­ster­ing the po­ten­tial...

Plus news about Boehringer, En­vis­agen­ics, Io­n­is, Ot­su­ka, Mer­ck, Lex­eo and Man­tle. 

Am­gen gets a win from Hori­zon buy­out: Am­gen saidda­zo­dal­ibep, a CD40 lig­and an­tag­o­nist...

Roche is back with more da­ta Tues­day for the lead drug it ob­tained from Car­mot Ther­a­peu­tics — this time from a mid-stage tri­al in over­weight...